QRG Capital Management Inc. Lowers Holdings in Merck & Co., Inc. $MRK

QRG Capital Management Inc. trimmed its stake in Merck & Co., Inc. (NYSE:MRK) by 14.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 428,993 shares of the company’s stock after selling 70,739 shares during the quarter. QRG Capital Management Inc.’s holdings in Merck & Co., Inc. were worth $55,126,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. BlackRock Inc. boosted its stake in Merck & Co., Inc. by 0.5% in the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares in the last quarter. State Street Corp increased its stake in Merck & Co., Inc. by 0.9% during the 2nd quarter. State Street Corp now owns 120,413,256 shares of the company’s stock valued at $15,573,754,000 after purchasing an additional 1,087,583 shares in the last quarter. Wellington Management Group LLP raised its holdings in Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock worth $11,083,033,000 after buying an additional 1,934,312 shares during the last quarter. Geode Capital Management LLC raised its holdings in Merck & Co., Inc. by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company’s stock worth $6,307,572,000 after buying an additional 249,110 shares during the last quarter. Finally, Norges Bank bought a new position in shares of Merck & Co., Inc. in the fourth quarter worth approximately $3,997,933,000. 76.07% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Pipeline catalysts could drive a re-rating. Bank of America maintained its Buy rating after meetings with Merck’s chief medical officer, citing multiple potential oncology and other clinical readouts over the next 12–18 months. Positive data could improve confidence in Merck’s post-KEYTRUDA growth outlook. Merck pipeline seen driving potential re-rating as clinical catalysts approach
• Positive Sentiment: WINREVAIR received a meaningful U.S. label expansion. The FDA approved updated labeling incorporating Phase 3 HYPERION data for recently diagnosed adults with pulmonary arterial hypertension. The change broadens the therapy’s supported clinical use and may strengthen WINREVAIR’s contribution to Merck’s growth. FDA approves WINREVAIR label update
• Positive Sentiment: Japan approved subcutaneous KEYTRUDA QLEX. The formulation gives patients and clinicians an alternative to intravenous administration across existing local indications, potentially improving convenience and supporting KEYTRUDA’s commercial durability in an important market. Japan clears new KEYTRUDA dosing option
• Neutral Sentiment: Analyst coverage remains broadly favorable, with Merck carrying an average Buy-equivalent recommendation. However, the stock’s elevated valuation means positive ratings may already reflect considerable optimism. Wall Street analysts assess Merck
• Negative Sentiment: Profit-taking risk is rising. Merck has substantially outperformed the broader market over the past year, prompting concerns that the rally has outpaced near-term fundamentals. A valuation near 118 times earnings could leave MRK vulnerable if clinical results disappoint or pipeline progress is delayed. Merck’s rally and profit-taking risks

Merck & Co., Inc. Stock Performance

MRK stock traded down $2.84 during trading on Wednesday, reaching $148.07. The stock had a trading volume of 9,631,266 shares, compared to its average volume of 10,787,158. The firm has a market cap of $365.31 billion, a PE ratio of 118.46, a PEG ratio of 6.51 and a beta of 0.21. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. The stock’s 50 day moving average is $139.57 and its two-hundred day moving average is $125.66. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the previous year, the company posted $2.13 EPS. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.76 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP David Williams sold 52,847 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the transaction, the executive vice president directly owned 31,716 shares in the company, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the transaction, the executive vice president owned 46,613 shares in the company, valued at $6,106,303. This represents a 24.35% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 228,238 shares of company stock valued at $29,977,783. 0.17% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on MRK shares. JPMorgan Chase & Co. raised their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Monday, July 13th. HSBC increased their target price on Merck & Co., Inc. from $150.00 to $172.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Barclays lifted their target price on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. The Goldman Sachs Group boosted their price target on Merck & Co., Inc. from $140.00 to $160.00 and gave the stock a “buy” rating in a research note on Friday, August 21st. Finally, Wells Fargo & Company upped their price target on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a report on Friday, September 4th. Seventeen analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $154.24.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.